Navigation Links
Sutro Biopharma Forges Partnership with Pfizer for Discovery, Development and Commercialization of Novel Peptide-Based Therapeutics
Date:1/7/2011

SAN FRANCISCO, Jan. 7, 2011 /PRNewswire/ -- Sutro Biopharma, a biopharmaceutical company developing novel and biosuperior protein therapeutics with improved pharmaceutical properties, today announced that the company has entered into a multi-year collaboration with Pfizer for the research, development and commercialization of novel peptide-based therapeutics.

Under the terms of the agreement, Sutro Biopharma will receive an upfront payment of an undisclosed amount, and Pfizer will provide Sutro with ongoing research funding. Sutro is eligible to receive development milestone payments and royalties upon commercialization of any products that may result from the collaboration. Additional details of the partnership were not disclosed.

"We are pleased to enter into this collaboration with Pfizer because it provides validation for the potential of our technology platform," said William Newell, chief executive officer of Sutro Biopharma. "This is another milestone in the maturation of the company as we move toward identification of our first drug candidates."

Sutro Biopharma recently secured $36.5 million in a Series C financing and announced the appointment of Trevor Hallam, Ph.D., as chief scientific officer. This is the first major collaboration announced by the company.

"This partnership gives Pfizer access to peptides that have been difficult to produce using conventional technologies," said Jaume Pons, Ph.D., vice president and chief scientific officer at Pfizer's Rinat subsidiary. "Sutro's open biochemical protein synthesis technology platform potentially resolves many of the problems inherent in other approaches, and we are looking forward to the mutual success of our collaboration."

About Sutro BiopharmaSutro Biopharma is a biopharmaceutical company that develops and designs novel protein therapeutics and biosuperiors that have site-directed modifications, including modifications incorporating non-natural amino acids. Sutro's biochemical protein synthesis technology opens up opportunities to create protein therapeutics that cannot be produced using conventional methods. Sutro's technology enables the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once identified, the company can efficiently scale production to commercial levels. In addition to developing its own drug pipeline, Sutro is collaborating with select pharmaceutical and biotechnology companies in the development of novel protein therapeutics that cannot be designed, produced or studied with current technologies.Media Contacts:David Schull or Martina Schwarzkopf, Ph.D.Russo Partners(212) 845-4271 (212) 845-4292 (347) 591-8785 (mobile)david.schull@russopartnersllc.commartina.schwarzkopf@russopartnersllc.com
'/>"/>

SOURCE Sutro Biopharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2017)... ... July 13, 2017 , ... Dr. Joshua Mondlick has introduced the LANAP® protocol ... Mondlick Perio, in the Phoenix area. Dr. Mondlick is at the forefront ... cleared laser treatment to re-grow bone and with significantly less pain than traditional surgery ...
(Date:7/13/2017)... (PRWEB) , ... July 13, 2017 , ... Thousands of ... and August for the National Aeromodeling Championships (Nats). Pilots come to Muncie to compete ... to earn spots on US teams that participate in world championships. , RC Pylon ...
(Date:7/13/2017)... , ... July 13, 2017 , ... ... two spectrophotometer calibration standards. Blast forward seven years and now they are ... holmium oxide for wavelength accuracy, and resolution testing. , ...
(Date:7/13/2017)... ... July 13, 2017 , ... Trinity Sterile, ... reusable medical supplies has chosen The Copley Consulting Group to implement and deploy ... to align its internal and backend operations to streamline efficiencies to meet the ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at ... between startups and global businesses, taking place in ... startups will showcase the solutions they have built with IBM ... France is one of the most ... increase in the number of startups created between 2012 and ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):